Total Voting Rights and Block Listing Return
Source: RNS
Total Voting Rights and Block Listing Return
Total Voting Rights
Guildford, UK - 1 July 2022: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.
The Company's issued share capital as at 30 June 2022 consisted of 49,880,029 shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.
Block Listing Six Monthly Return
|
Name of applicant: |
Ergomed plc |
|||
|
Name of scheme: |
Ergomed plc Long Term Incentive Plan |
|||
|
Period of return: |
From: |
1 January 2022 |
To: |
30 June 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
1,908,177 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
0 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
586,400 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
1,321,777 |
|||
|
Number and class of securities originally admitted and the date of admission |
1,800,000 ordinary shares of 1p each - 2 July 2018 1,500,000 ordinary shares of 1p each - 31 December 2019 600,000 ordinary shares of 1p each - 7 July 2021 |
|||
|
Total number of securities in issue at the end of the period |
49,880,029 ordinary shares of 1p each |
|||
|
Name of contact: |
Fiona Mundy - Director of Group Reporting |
|
Telephone number of contact: |
+44 (0) 7854825324 |
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
